AKTIP

AKTIP is a UEV-domain protein that operates at the intersection of telomere maintenance, nuclear architecture, cytokinetic abscission, and AKT signaling. At telomeres, AKTIP binds shelterin components TRF1 and TRF2 as well as replication factors PCNA and RPA70, and cooperates with TRF1 to facilitate telomeric DNA replication during S phase; its depletion causes telomere dysfunction foci, replication-associated telomeric aberrations, and intra-S checkpoint activation (PMID:26110528). AKTIP interacts with A- and B-type lamins at the nuclear envelope, requires functional lamin A for proper localization, and its mislocalization—as seen in progerin-expressing cells—links nuclear lamina integrity to AKTIP positioning (PMID:27512140, PMID:36096808). During cytokinesis, AKTIP functions as an ESCRT I component at the midbody, where it is recruited in an MKLP1-dependent manner, binds VPS28, and cooperates with TSG101 to recruit ESCRT III subunits CHMP4B and IST1 for abscission; its depletion causes multinucleation (PMID:34449766).

1. 2015 High

   The question of whether AKTIP has a direct role at telomeres was answered by demonstrating that it physically binds shelterin (TRF1/TRF2), occupies telomeric chromatin, and is required for telomeric DNA replication, establishing it as a novel replication-facilitating telomere factor.

   Evidence Co-IP, in vitro pulldown, ChIP, RNAi, epistasis with TRF1 for MTS formation in MEFs

   PMID:26110528

   Open questions at the time

   • Structural basis of AKTIP–TRF1 interaction unknown
   • Whether AKTIP participates in telomere replication through its UEV domain or another surface is unresolved
   • In vivo organismal consequences of telomere-specific AKTIP loss not tested
2. 2016 High

   Whether AKTIP connects to nuclear architecture beyond telomeres was resolved by showing it interacts with A- and B-type lamins, localizes to the nuclear rim dependently on lamin A, and its loss induces senescence-associated phenotypes, linking AKTIP to nuclear envelope integrity.

   Evidence Co-IP with lamins, co-localization imaging, siRNA knockdown with senescence marker readouts

   PMID:27512140

   Open questions at the time

   • Whether lamin interaction and telomere function are mechanistically coupled is unclear
   • Direct binding domain on AKTIP for lamins not mapped
   • Whether AKTIP loss-induced senescence is telomere-driven or lamin-driven not distinguished
3. 2021 High

   The long-standing observation that AKTIP localizes to the midbody was mechanistically resolved: AKTIP acts as an ESCRT I component that binds VPS28, is recruited by MKLP1 independently of CEP55, and cooperates with TSG101 to recruit ESCRT III subunits for cytokinetic abscission.

   Evidence Co-IP, super-resolution imaging, single and double siRNA knockdown with ESCRT subunit recruitment epistasis and multinucleation quantification

   PMID:34449766

   Open questions at the time

   • Whether AKTIP replaces or supplements TSG101-VPS28 in canonical ESCRT I is unresolved
   • Stoichiometry and structure of AKTIP-containing ESCRT I complex not determined
   • Relationship between AKTIP's midbody and telomere functions during the cell cycle not tested
4. 2021 Medium

   How AKTIP participates in AKT activation was clarified by identifying TLK1-mediated phosphorylation of AKTIP at T22 and S237, which enhances AKT–PDK1 association and AKT phosphorylation, placing AKTIP as a phospho-regulated scaffold in a TLK1→AKTIP→AKT axis.

   Evidence Phosphoproteomics, co-IP, TLK1 inhibitor and siRNA in prostate cancer cells

   PMID:35366279

   Open questions at the time

   • Functional rescue with phospho-mimetic or phospho-dead AKTIP mutants not performed
   • Whether TLK1-AKTIP signaling operates in non-cancer contexts is untested
   • Direct binding interface between AKTIP and AKT/PDK1 not mapped
5. 2022 Medium

   AKTIP's role in cancer cell signaling was expanded by showing that its loss stabilizes ERα through a CAND1/cullin 2-dependent mechanism and activates JAK2-STAT3 as a compensatory survival pathway, conferring ERα-antagonist resistance in breast cancer.

   Evidence siRNA/shRNA, co-IP, proteasome inhibitor rescue, ERα reporter assay, patient-derived organoids, pharmacological JAK2/STAT3 inhibition

   PMID:36516775

   Open questions at the time

   • Whether AKTIP directly interacts with cullin 2 or CAND1 is not established
   • Mechanism by which AKTIP loss activates JAK2-STAT3 is indirect and not fully delineated
   • Generalizability beyond ERα-positive breast cancer unknown
6. 2022 Medium

   The dependence of AKTIP localization on nuclear lamina integrity was refined by showing that progerin expression, but not EDMD2 lamin A mutations, mislocalizes AKTIP, indicating nuclear morphology rather than lamin expression level dictates AKTIP positioning.

   Evidence Super-resolution imaging and quantitative co-localization in HGPS, EDMD2, tumor, and progerin-transfected cells

   PMID:36096808

   Open questions at the time

   • Functional consequence of AKTIP mislocalization on telomere or ESCRT functions in laminopathy cells not tested
   • Whether AKTIP mislocalization in tumor cells contributes to genome instability is unresolved

• A unified model explaining how AKTIP's telomere replication, nuclear lamina, ESCRT I/abscission, and AKT signaling functions are coordinated across the cell cycle remains to be established.
• No structural data for AKTIP in any of its functional complexes
• How the UEV domain contributes to each distinct function is not dissected
• Whether AKTIP's separate roles are independent or mechanistically linked is unknown